EUVIMEDEUVIMED entdecken
Open Access

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway

Dexue Fan, Wei Su, Zhaowen Bi, Xinxing Wang, Xianwen Xu, Mingze Ma, Lichao Zhu, Zhenhai Zhang, Junlin Gao

Oncology Research · 2025

DOI: 10.32604/or.2025.060407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Dexue Fan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China. Hauptthemen laut MEDLINE: Sorafenib, Pyridines, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibPyridinesLiver NeoplasmsDrug Resistance, NeoplasmCarcinoma, HepatocellularMAP Kinase Signaling SystemHumansErbB ReceptorsAnimalsHep G2 CellsMiceEpithelial-Mesenchymal TransitionXenograft Model Antitumor AssaysAntineoplastic AgentsProtein Kinase InhibitorsCell ProliferationSignal Transduction

Stichwörter der Autor:innen

ApatinibEGFR/JNK/ERKEpithelial mesenchymal transformationHepatocellular carcinoma (HCC)Sorafenib resistance

Substanzen

SorafenibapatinibPyridinesErbB ReceptorsEGFR protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
  • Liver Gall Bladder and Pancreatic Surgery Ward, Qinghai Red Cross Hospital, Xining, 810001, China.
  • Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, China.
  • Departments of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
  • Department of Pediatric Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, China.

Zitieren

APA

Fan, D., Su, W., Bi, Z., Wang, X., Xu, X., Ma, M., Zhu, L., Zhang, Z., & Gao, J. (2025). Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. Oncology Research. https://doi.org/10.32604/or.2025.060407

Vancouver

Fan D, Su W, Bi Z, Wang X, Xu X, Ma M, et al. Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. Oncology Research. 2025. doi:10.32604/or.2025.060407

BibTeX
@article{Fan2025,
  author = {Fan, Dexue and Su, Wei and Bi, Zhaowen and Wang, Xinxing and Xu, Xianwen and Ma, Mingze and Zhu, Lichao and Zhang, Zhenhai and Gao, Junlin},
  title = {Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.060407}
}
Kostenlos starten →